

## REQUEST FOR EXPRESSIONS OF INTEREST CONSULTING SERVICES

Selection # RG-T3919-P001

Selection Method: Competitive selection

Country: Regional

Sector: Regional Integration Unit (INT) and the Social Protection and Health Division (SCL/SPH)

Funding - TC #: ATN/CF-18701-RG

Project #: RG-T3919

TC name: Scaling up Immunization Capacities in PROSUR Countries

## **Description of Services:**

Link to TC document: <a href="https://www.iadb.org/projects/document/EZSHARE-43721649-25?project=RG-T3919">https://www.iadb.org/projects/document/EZSHARE-43721649-25?project=RG-T3919</a>

The Inter-American Development Bank (IDB) is executing the above-mentioned operation. For this operation, the IDB intends to contract consulting services described in this Request for Expressions of Interest.

Expressions of interest must be delivered using the IDB Portal for Bank Executed Operations (<a href="http://beo-procurement.iadb.org/home">http://beo-procurement.iadb.org/home</a>) by: 31<sup>st</sup> of October at 5:00 P.M. (Washington D.C. Time).

The consulting services ("the Services") include:

- 1. Proposed new vaccine production facility pre-feasibility study.
  - a. The Firm is to conduct a pre-feasibility study for the type of facility agreed upon in Phase 1. The study should identify enablers and barriers for the new facility to be able to operate in a sustainable manner.
  - b. The Firm must then recommend potential solutions for these gaps, especially ones which can be effectively implemented by governments or through government support and evaluate the feasibility the proposed solutions can be implemented successfully<sup>1</sup>. A recommendation on where the facility should be located must also be made if a location wasn't already agreed as part of Phase 1.
  - c. The Firm must deliver a high level production facility business case which covers the following: Estimated capital expense (CAPEX), operational expense (OPEX) and Cost of Goods (COGs) for the products to be made there, an explanation of the scope of the facility (capacity during pandemic and non-pandemic times, production steps and technologies to be employed), timeline for facility build and licensure and finally the economies of scale and internal operational considerations (facility utilization, product portfolio, etc) needed for the facility to be viable in both pandemic and non-pandemic times. A preliminary financial model including CAPEX, OPEX and COGs estimates should be created to detail the overall financial viability of the facility over the initial 5-10 years of operation.
  - d. The Firm will participate in a series of meetings to keep the Steering Committee and Member States abreast of the findings of the pre-feasibility study as it is being conducted.
- 2. Co-develop, facilitate, and actively participate in workshops to define a strategic roadmap for implementing new vaccine manufacturing facility.
  - a. A workshop will be held where the final recommended concept package for the new vaccine facility will be presented by the Firm to Member States for validation<sup>2</sup>. If the outcome of the pre-feasibility

<sup>&</sup>lt;sup>1</sup> Factors which could be used to gauge the feasibility a solution would work include but are not limited to: Firm's experience on other projects/case studies from similar situations, the degree to which it aligns with what Member states have already agreed to, ongoing discussions with Steering Committee members or Member States. The gap closure solutions will ultimately be pressure tested during Activity 9.

<sup>&</sup>lt;sup>2</sup> This validation must also explicitly include at least preliminary approval of the incentives and support required for the facility from Member States or other organizations who must provide them.

- study is positive, the concept package will serve as the foundation of what will be used to engage potential financiers, technology transfer partners, facility design firms and other firms required for the project.
- b. The Firm will create a roadmap for the implementation of the approved facility concept package. The roadmap shall layout the steps required to progress from the end of the pre-feasibility study through to final facility project execution. It must also include a list of roles and responsibilities for the entities required to progress through this roadmap. A final workshop will be held for Member States to review and validate the roadmap.
- 3. Co-develop, facilitate, and actively participate in a public/private forum to socialize the results of pre-feasibility and discuss the roadmap
  - a. Firm(s) shall present an overview of the roadmap and pre-feasibility and how they lead to the final recommendations which were approved by Member States.
  - b. Forum attendees to provide feedback, pressure test the concepts and express willingness or ability to participate in such a cooperative agreement
  - c. Forum attendees to include but are not limited to: representatives from Member States, the Bank, global health organizations (i.e., PAHO, WHO, CEPI, COVAX), local vaccine and pharmaceutical manufacturers and other actors in the local vaccine supply chain.

The services should be completed and accepted by the Bank on the third week of April 2022.

Firms who apply must have experience executing at least three projects with a value greater than \$100,000 in the below areas. To demonstrate this experience, the Firm must provide a brief description of the relevant projects as well as 3 client references.

- Support and guidance to national governments on immunization, vaccine procurement or vaccine manufacturing policy; and/or
- Execution of vaccine manufacturing feasibility studies, including a financial model of the proposed facility, which assessed the various ecosystem factors detailed in the TOR below

The Firm must provide financial statements for the past three year which demonstrate the Firm's financial stability

Proposals from multiple Firms working in a Consortium or where a Firm will use sub-contractors must demonstrate that the various team members have worked together successfully on past projects.

The Firm must declare any potential vested interests or conflicts of interest with any ongoing vaccine manufacturing or related project in the LAC region

Eligible consulting firms will be selected in accordance with the procedures set out in the Inter-American Development Bank: <u>Policy for the Selection and Contracting of Consulting firms for Bank-executed Operational Work</u> - GN-2765-4. All eligible consulting firms, as defined in the Policy may express an interest. If the Consulting Firm is presented in a Consortium, it will designate one of them as a representative, and the latter will be responsible for the communications, the registration in the portal and for submitting the corresponding documents.

The IDB now invites eligible consulting firms to indicate their interest in providing the services described above in the <u>draft summary</u> of the intended Terms of Reference for the assignment. Interested consulting firms must provide information establishing that they are qualified to perform the Services (brochures, description of similar assignments, experience in similar conditions, availability of appropriate skills among staff, etc.). Eligible consulting firms may associate in a form of a Joint Venture or a sub-consultancy agreement to enhance their qualifications. Such association or Joint Venture shall appoint one of the firms as the representative.

Interested eligible consulting firms may obtain further information during office hours, 09:00 AM to 05:00 PM, (Washington D.C. Time) by sending an email to: Alejandra Radl (<a href="mailto:alejandrara@iadb.org">alejandrara@iadb.org</a>) and a copy to Jaime Cardona (<a href="mailto:jaimecar@iadb.org">jaimecar@iadb.org</a>) and Bill Savedoff (<a href="mailto:wsavedoff@iadb.org">wsavedoff@iadb.org</a>)

Inter-American Development Bank

Division: *SCL/SPH*Attn: *Alejandra Radl* 

1300 New York Ave, NW, Washington DC 20577, USA

Tel: +1 202 623-2962; (5411) 4323-2360

 $\textbf{E-mail:} \ \underline{alejandrara@iadb.org} \ ; \underline{\textit{wsavedoff@iadb.org}} \ ; \underline{\textit{yiaimecar@iadb.org}} \ ; \underline{\textit{alejandrara@iadb.org}} \ ; \underline{\textit{alejandrara@iadb.or$ 

Web site: www.iadb.org